Preview complete
The prescreener preview is complete. You may now close the preview.
Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY
Call 1800-9860-568 now to find out if you are eligible.
Are you a patient with moderate to severe plaque psoriasis?
Have you treated your condition with adalimumab (Humira®) and did it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis. Qualified participants will receive an initial consultation, study-related examinations, and study medication.
Check your eligibility
Take up this questionnaire to help us determine if you have symptoms
that are common to this clinical study. If you have the common
symptoms, you may be eligible to take part in the study.
Age
None - None
Gender
All
NCT ID
TX7789
Phase
None
Status
Recruiting Now
Medical Condition
How is Plaque Psoriasis treated?
Medical Condition
A short sentence to introduce what to expect in the about condition
section
Learn moreThe Study
A short sentence to introduce what to expect in the about condition
section
Learn moreAbout Clinical Trials
A short sentence to introduce what to expect in the about condition
section
Learn moreYour Journey
01
Receiving the medication
You would receive etanercept (Enbrel) twice a week for 12 weeks and
then once a week for 12 weeks. Etanercept, as well as study related
medical care, is provided at no cost.
02
Visiting the study site
Study participation involves approximately 8 visits to your local
study center over 6 to 7 months.
03
Follow-up
There would also be a follow-up telephone call 30days after
completing the study. No visits are required after participation is
complete.